Comparative Pharmacology
Head-to-head clinical analysis: ISMOTIC versus MANNITOL 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISMOTIC versus MANNITOL 15.
ISMOTIC vs MANNITOL 15%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing intracranial pressure and intraocular pressure. Acts as an osmotic diuretic in the kidneys, increasing urine flow by inhibiting water reabsorption in the proximal tubule and loop of Henle.
1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.
1-2 g/kg as a 15% solution intravenously over 30-60 minutes. Typical adult dose: 100-200 g (667-1333 mL of 15% solution) administered as a single dose for reduction of intracranial pressure or promotion of diuresis.
None Documented
None Documented
4.5-6.0 hours in adults with normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria)
Terminal elimination half-life approximately 0.25-1.5 hours in normal renal function; prolonged to 24-36 hours in renal impairment.
Renal: 90-95% unchanged; biliary/fecal: <5%
Primarily renal (90-100% as unchanged drug); negligible biliary/fecal elimination.
Category C
Category A/B
Osmotic Diuretic
Osmotic Diuretic